The OIE represents 178 Member countries and territories with international surveillance programmes that monitor antigenic drift among equine influenza viruses, and its Expert Surveillance Panel (ESP) for EIV makes annual recommendations for the composition of equine vaccines.
ProteqFlu, manufactured by Merial Animal Health, is currently the only vaccine in Europe to meet these recommendations.
Brand manager Dr Clare Turnbull said: "These recommendations, which have been in place since 2011, call for the inclusion of both Florida Clade 1 and 2 strains; as these are representative of the EIV strains that competing horses encounter globally.
"Although all licensed vaccinations should give clinical protection to individuals when challenged with a heterologous strain, mathematical modelling demonstrates that when scaled up to population level, this mis-match between challenge strain and vaccine strain significantly increases the risk of an epidemic occurring."
The FEI imposes mandatory equine influenza vaccination for horses competing under their jurisdiction to improve equine welfare by reducing clinical disease in individuals; but also because of the financial losses that an outbreak could have on the equine sport industry.
Göran Akerstrom, veterinary director of the FEI said: "The FEI has been a part of a Public Private Partnership with OIE for many years and we admire the work that they do in disease surveillance and global animal health.
"We stand behind their recommendations on vaccination for equine influenza and recommend our athletes to discuss these with their veterinary surgeons when considering their vaccination schedules."
For further information on FEI vaccination requirements visit https://inside.fei.org/node/3289
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.